Edwards Lifesciences Corporation (EW) Shares are Up 1.75%

Edwards Lifesciences Corporation (EW) : Traders are bullish on Edwards Lifesciences Corporation (EW) as it has outperformed the S&P 500 by a wide margin of 0.8% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.21%, relative to the S&P 500. The stock has risen by 1.75% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.25% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 0.61% and the 50-Day Moving Average is 3.77%.The 200 Day SMA reached 20.83% Edwards Lifesciences Corp. is up 18.33% in the last 3-month period. Year-to-Date the stock performance stands at 47.63%.


Edwards Lifesciences Corporation (EW) : 14 investment research analysts covering Edwards Lifesciences Corporation (EW) have an average price target of $126.36 for the near short term. The highest target price given by the Brokerage Firm to the stock is $140 and the lowest target is $105 for the short term. Analysts expect the variance to be within $10.13 of the average price.

For the current week, the company shares have a recommendation consensus of Buy. Edwards Lifesciences Corporation (NYSE:EW): stock was range-bound between the intraday low of $116.137 and the intraday high of $117.17 after having opened at $117 on Fridays session. The stock finally closed in the red at $117, a loss of -0.32%. The stock remained in the red for the whole trading day. The total traded volume was 1,476,041 shares. The stock failed to cross $117.17 in Fridays trading. The stocks closing price on Thursday was $116.97.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.